<code id='3CB2D0D265'></code><style id='3CB2D0D265'></style>
    • <acronym id='3CB2D0D265'></acronym>
      <center id='3CB2D0D265'><center id='3CB2D0D265'><tfoot id='3CB2D0D265'></tfoot></center><abbr id='3CB2D0D265'><dir id='3CB2D0D265'><tfoot id='3CB2D0D265'></tfoot><noframes id='3CB2D0D265'>

    • <optgroup id='3CB2D0D265'><strike id='3CB2D0D265'><sup id='3CB2D0D265'></sup></strike><code id='3CB2D0D265'></code></optgroup>
        1. <b id='3CB2D0D265'><label id='3CB2D0D265'><select id='3CB2D0D265'><dt id='3CB2D0D265'><span id='3CB2D0D265'></span></dt></select></label></b><u id='3CB2D0D265'></u>
          <i id='3CB2D0D265'><strike id='3CB2D0D265'><tt id='3CB2D0D265'><pre id='3CB2D0D265'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:71171
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Results on Novartis prostate cancer therapy could expand its use
          Results on Novartis prostate cancer therapy could expand its use

          TheNovartisboothatESMO2023inMadrid.AndrewJoseph/STATMADRID—ResultspresentedMondaycouldexpandtheuseof

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Merck, Daiichi strike cancer drug pact worth up to $22 billion

          KenaBetancur/GettyImagesMADRID—MerckispayingbillionsofdollarstopartnerwithDaiichiSankyoonaseriesofca